- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07570160
Intranasal Dexmedetomidine or Esketamine for Negative Postoperative Behavioral Changes in Children (PEDI-NPOBCs)
Exploring the Association of Perioperative Electroencephalographic Changes Following Preoperative Intranasal Dexmedetomidine or Esketamine With Negative Postoperative Behavioral Changes in Children Undergoing Day Surgery
The goal of this clinical trial is to learn whether intranasal dexmedetomidine or esketamine given before anesthesia can reduce negative postoperative behavioral changes in children undergoing day surgery. Negative postoperative behavioral changes may include anxiety, sleep problems, nightmares, irritability, or other unusual behaviors after surgery. This study will also examine whether changes in brain wave patterns during the perioperative period are related to these behavioral changes.
The main questions this study aims to answer are:
Does intranasal dexmedetomidine reduce negative postoperative behavioral changes in children after day surgery? Does intranasal esketamine reduce negative postoperative behavioral changes in children after day surgery? Are perioperative electroencephalographic (EEG) features associated with negative postoperative behavioral changes? Researchers will compare intranasal dexmedetomidine, intranasal esketamine, and normal saline to see whether these treatments differ in their effects on postoperative behavior and perioperative EEG features.
Participants will be randomly assigned to receive intranasal dexmedetomidine, intranasal esketamine, or intranasal normal saline about 30 minutes before anesthesia. They will receive routine perioperative monitoring, including EEG monitoring during surgery and recovery. They will also be assessed for sedation, pain, and emergence delirium. Follow-up assessments of postoperative behavioral changes will be completed on postoperative days 3, 7, and 28.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
This multicenter, prospective, randomized, double-blind, controlled clinical trial will evaluate whether preoperative intranasal dexmedetomidine or esketamine can reduce negative postoperative behavioral changes in children undergoing day surgery under general anesthesia. The study will also explore whether perioperative electroencephalographic (EEG) features are associated with these behavioral changes and may help explain the effects of the study drugs.
A total of 342 children undergoing elective day surgery will be enrolled across four centers. Eligible participants will be randomly assigned in a 1:1:1 ratio to receive intranasal dexmedetomidine 2.0 micrograms/kg, intranasal esketamine 1.0 mg/kg, or an equal volume of normal saline approximately 30 minutes before induction of anesthesia. Study medications will be prepared in identical, unlabeled nasal spray devices to maintain blinding. Participants, investigators, and outcome assessors will remain unaware of treatment assignment throughout the study.
After study drug administration, participants will undergo routine perioperative monitoring. Sedation will be assessed before surgery. During anesthesia and recovery, EEG and other perioperative clinical data will be collected. Postoperative assessments will include pain and emergence delirium. Negative postoperative behavioral changes will be evaluated on postoperative days 3, 7, and 28. The primary outcome is the incidence of negative postoperative behavioral changes on postoperative day 7. Secondary analyses will assess behavioral outcomes at postoperative days 3 and 28 and examine the relationship between perioperative EEG patterns and postoperative behavioral changes.
This study is designed to provide evidence on the comparative effects of intranasal dexmedetomidine and esketamine on postoperative behavioral recovery in children undergoing day surgery and to identify perioperative EEG markers that may be associated with adverse behavioral outcomes.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 4
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Li Zhang, Doctoral degree
- Puhelinnumero: +86 138 1540 6629
- Sähköposti: drzhangli@njmu.edu.cn
Tutki yhteystietojen varmuuskopiointi
- Nimi: Fei Sun, Master's degree
- Puhelinnumero: +86 181 0061 9994
- Sähköposti: drsunfei89@163.com
Opiskelupaikat
-
-
Jiangsu
-
Nanjing, Jiangsu, Kiina, 210008
- Children's Hospital of Nanjing Medical University
-
Ottaa yhteyttä:
- Medical Ethics Committee of Children's Hospital of Nanjing Med
- Puhelinnumero: +86 189 5176 2937
- Sähköposti: drsunfei@njmu.edu.cn
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Children aged 2 to 12 years.
- Scheduled to undergo elective day surgery under general anesthesia.
- ASA (American Society of Anesthesiologists) physical status I to III.
Exclusion Criteria:
- Congenital diseases or severe liver or kidney dysfunction.
- History of allergic reactions to study drugs.
- Neuromuscular diseases, cerebral palsy, epilepsy.
- Other psychiatric or neurological disorders.
- Body mass index (BMI) ≥ 30 kg/m².
- Severe upper respiratory tract infections prior to surgery.
- Use of sedatives or analgesics within 48 hours before surgery.
- Exposure to major life stressors within 1 month before surgery (e.g., family separation, death of a parent).
- Refusal to participate or failure to obtain consent from the child's legal guardian.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Intranasal Dexmedetomidine
Participants receive intranasal dexmedetomidine 2.0 micrograms/kg approximately 30 minutes before induction of general anesthesia.
|
Intranasal dexmedetomidine 2.0 micrograms/kg administered once approximately 30 minutes before induction of general anesthesia.
Muut nimet:
|
|
Kokeellinen: Intranasal Esketamine
Participants receive intranasal esketamine 1.0 mg/kg approximately 30 minutes before induction of general anesthesia.
|
Intranasal esketamine 1.0 mg/kg administered once approximately 30 minutes before induction of general anesthesia.
Muut nimet:
|
|
Placebo Comparator: Normal Saline Control
Participants receive an equal volume of intranasal normal saline approximately 30 minutes before induction of general anesthesia.
|
Intranasal normal saline of equal volume administered once approximately 30 minutes before induction of general anesthesia.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 7
Aikaikkuna: Postoperative Day 7
|
Incidence of negative postoperative behavioral changes assessed using the Post Hospitalization Behavior Questionnaire for Ambulatory Surgery (PHBQ-AS).
|
Postoperative Day 7
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 3
Aikaikkuna: Postoperative Day 3
|
Incidence of negative postoperative behavioral changes assessed using the Post Hospitalization Behavior Questionnaire for Ambulatory Surgery (PHBQ-AS).
|
Postoperative Day 3
|
|
Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 28
Aikaikkuna: Postoperative Day 28
|
Incidence of negative postoperative behavioral changes assessed using the Post Hospitalization Behavior Questionnaire for Ambulatory Surgery (PHBQ-AS).
|
Postoperative Day 28
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Sedation Score 30 Minutes After Study Drug Administration
Aikaikkuna: 30 minutes after study drug administration
|
Sedation level assessed 30 minutes after study drug administration using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale.
Scores range from 0 to 5, with 0 indicating no response to painful stimulus and 5 indicating fully alert.
Higher scores indicate better alertness and less sedation.
|
30 minutes after study drug administration
|
|
Postoperative Pain Score
Aikaikkuna: At the time of emergence in the post-anesthesia care unit
|
Pain intensity assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale.
Scores range from 0 to 10, with higher scores indicating worse pain.
|
At the time of emergence in the post-anesthesia care unit
|
|
Emergence Delirium Score
Aikaikkuna: After emergence in the post-anesthesia care unit
|
Emergence delirium assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale.
Scores range from 0 to 20, with higher scores indicating worse emergence delirium.
|
After emergence in the post-anesthesia care unit
|
|
Intraoperative Electroencephalographic Parameters Before Emergence Description
Aikaikkuna: From induction of anesthesia until before emergence
|
Electroencephalographic parameters derived from raw intraoperative electroencephalography recordings obtained from after induction of anesthesia until before emergence.
Reported values will be summarized from the recorded electroencephalographic data.
|
From induction of anesthesia until before emergence
|
|
Incidence of Perioperative Adverse Events
Aikaikkuna: From administration of study drug until discharge from the post-anesthesia care unit, assessed up to the maximum expected PACU stay (varies by individual, typically 1-4 hours)
|
Incidence of perioperative adverse events, including nausea, vomiting, allergic reactions, emergence delirium, and other adverse behavioral or physiological events occurring in children during the immediate postoperative period.
All adverse events are continuously monitored and recorded by trained clinical staff using standardized observation procedures and behavioral scales (e.g., PAED scale for emergence delirium).
The observation period includes the entire post-anesthesia care unit stay until the child meets discharge criteria.
|
From administration of study drug until discharge from the post-anesthesia care unit, assessed up to the maximum expected PACU stay (varies by individual, typically 1-4 hours)
|
|
Emergence Time
Aikaikkuna: In the post-anesthesia care unit on the day of surgery
|
Time from discontinuation of anesthesia to emergence.
|
In the post-anesthesia care unit on the day of surgery
|
|
Postoperative Time to Discharge
Aikaikkuna: From end of surgery to discharge on the day of surgery
|
Time from the end of surgery to hospital discharge.
|
From end of surgery to discharge on the day of surgery
|
|
Parental Satisfaction Score Assessed by the Pediatric Anesthesia Parent Satisfaction (PAPS) Questionnaire
Aikaikkuna: On the day of surgery before discharge
|
Parental satisfaction with perioperative management assessed on the day of surgery before discharge using the Pediatric Anesthesia Parent Satisfaction (PAPS) questionnaire.
The questionnaire includes 15 items, and total scores range from 15 to 75, calculated as the sum of all item scores.
Higher scores indicate greater parental satisfaction.
|
On the day of surgery before discharge
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: fei sun, Master's, Children's Hospital of Nanjing Medical University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Neurologiset ilmenemismuodot
- Hermoston sairaudet
- Postoperatiiviset komplikaatiot
- Patologiset prosessit
- Hämmennys
- Neurokäyttäytymisoireet
- Neurokognitiiviset häiriöt
- Delirium
- Patologiset tilat, merkit ja oireet
- Merkit ja oireet
- Deliriumin ilmaantuminen
- Mielenterveyshäiriöt
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Lääkevalmisteet
- Atsolit
- Imidatsolit
- Epäorgaaniset kemikaalit
- Klooriyhdisteet
- Kristalloidiliuokset
- Isotoniset ratkaisut
- Ratkaisut
- Natriumyhdisteet
- Kloridit
- Suolahappo
- Esketamiini
- Deksmedetomidiini
- Suolaliuos
- Natriumkloridi
Muut tutkimustunnusnumerot
- 202512066-2
- SWYY2025002065 (Muu apuraha/rahoitusnumero: ISEFC, China)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .